|
|
|
Arbutus Biopharma Appoints Andrew Cheng, M.D., Ph.D., to its Board of Directors
|
Burnaby, BC, August 28, 2019--Arbutus Biopharma Corporation(Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced that Andrew Cheng, M.D., Ph.D., has been appointed to the Arbutus Board of Directors effective August 17, 2019.
|
|
|
|
|
|
Arbutus Announces Preliminary Phase 1a/1b Clinical Trial Results for AB-506
|
Burnaby, BC, July 18, 2019-Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced preliminary results from a Phase 1a/1b clinical trial in healthy subjects and two cohorts of chronic hepatitis B (CHB) subjects who received AB-506 monotherapy.
|
|
|
|
|
|